Evaluation of the pharmacokinetics, safety and clinical efficacy of sertraline used to treat social anxiety

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 11, 2013, Pages 1495-1505

  Mandrioli, Roberto ^a   Mercolini, Laura ^a   Raggi, Maria Augusta ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Pharmacokinetics; Pharmacotherapy; Serotonin reuptake; Sertraline; Social anxiety

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CIMETIDINE; CLOZAPINE; DIAZEPAM; FLECAINIDE; HYPERICUM PERFORATUM EXTRACT; MONOAMINE OXIDASE INHIBITOR; PIMOZIDE; PROPAFENONE; SERTRALINE; SUMATRIPTAN; TOLBUTAMIDE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

AREA UNDER THE CURVE; BIRTH DEFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; REVIEW; SEXUAL DYSFUNCTION; SINGLE DRUG DOSE; SOCIAL PHOBIA; SUICIDAL IDEATION;

ANXIETY DISORDERS; DRUG EVALUATION, PRECLINICAL; HALF-LIFE; HUMANS; PHOBIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 84886019954     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.816675     Document Type: Review

References (118)

1. American Psychiatric Association, Diagnostic and statistical manual of mental disorders fifth edition (DSM-5). American Psychiatric Association, Arlington; 2013
2. Connor KM, Jonathan RT, Churchill LE, et al. Psychometric properties of the Social Phobia Inventory (SPIN): new self-rating scale. Br J Psychiatry 2000;176:379-86
3. Liebowitz MR. Social phobia. Mod Probl Pharm 1987;22:141-73
4. Beesdo K, Bittner A, Pine DS, et al. Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry 2007;64:903-12 (Pubitemid 47230614)
5. Blanco C, Garcia C, Liebowitz MR. Epidemiology of social anxiety disorder. In: Bandelow B, Stein DJ, editors. Social anxiety disorder. Marcel Dekker; New York: 2004
6. The numbers count: mental disorders in America. Social phobia. Rockville, MD: National Institute of Mental Health (NIMH), 2013. Available from: http://www.nimh.nih.gov/health/publications/the-numbers-count-mentaldisorders- in-america/index.shtml#Social [Last accessed 30 March 2013]
7. Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin 2012;16:77-84
8. Robinson HM, Hood SD. Social anxiety disorder-a review of pharmacological treatment. Curr Psychiatry Rev 2007;3:95-122 (Pubitemid 46773910)
9. Veale D. Treatment of social phobia. Adv Psychiatr Treat 2003;9:258-64 (Pubitemid 36806244)
10. Treatment Guidelines for Social Anxiety Disorder. Scarborough, Ontario: Anxiety Disorders Association of Canada/Association Canadienne des Troubles Anxieux (ADAC/ACTA), 2003. Available from: http://www. anxietycanada.ca/english/ pdf/sad-guidelines.pdf [Last accessed 30 March 2013]
11. Anxiety Disorders Drug Treatment Guidelines. Perth: psychotropic Drugs Committee of the Western Australian Therapeutics Advisory Group (WATAG), 2008. Available from: http://www.watag. org.au/wapdc/guidelines.cfm [Last accessed 30 March 2013]
12. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005;19:567-96 (Pubitemid 41578819)
13. Social anxiety disorder: recognition, assessment and treatment. London: National Collaborating Centre for Mental Health, 2012. Available from: http://www.nice.org.uk/nicemedia/live/12950/61875/61875.pdf [Last accessed 30 March 2013]
14. Jadresic E, S-uarez C, Palacios E, et al. Evaluating the efficacy of endoscopic thoracic sympathectomy for generalized social anxiety disorder with blushing complaints: a comparison with sertraline and no treatment-Santiago de Chile 2003-2009. Innov Clin Neurosci 2011;8:24-35
15. Fontani V, Mannu P, Castagna A, Rinaldi S. Social anxiety disorder: radio electric asymmetric conveyor brain stimulation versus sertraline. Patient Pref Adher 2011;5:581-6
16. Christensen H, Guastella AJ, Mackinnon AJ, et al. Protocol for a randomised controlled trial investigating the effectiveness of an online e-health application compared to attention placebo or sertraline in the treatment of generalised anxiety disorder. Trials 2010;11:art.n.48
17. Phan KL, Coccaro EF, Angstadt M, et al. Corticolimbic brain reactivity to social signals of threat before and after sertraline treatment in generalized social phobia. Biol Psychiatry 2013;73:329-36
18. Inoue T, Koyama T. Anxiety disorder. Brain Nerve 2012;64:131-8
19. Cipriani A, Furukawa TA, Geddes JR, et al. Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression A systematic review and meta-analysis. J Clin Psychiatry 2008;69:1732-42
20. Greenblatt DJ, Harmatz JS, Shader RI. Psychotropic drug prescribing in the United States: extent, costs, and expenditures. J Clin Psychopharmacol 2011;31:1-3
21. Ginsburg GS, Sakolsky D, Piacentini J, et al. Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol 2011;79:806-13
22. Sertraline approval history, NDA 019839, Supplement number 045. Washington, DC: FDA/Center for Drug Evaluation and Research, 2009. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2003/19839se1-045, 20990se1-011ltr.pdf [Last accessed 30 March 2013]
23. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995;152:1368-71
24. Van Ameringen M, Mancini C, Streiner D. Sertraline in social phobia. J Affect Disord 1994;31:141-5 (Pubitemid 24183902)
25. Munjack DJ, Flowers C, Eagan TV. Sertraline in social phobia. Anxiety 1994;1:196-8
26. Sokolenko M, Kutcher S. Sertraline for social anxiety disorder. Exp Rev Neurother 2003;3:787-95 (Pubitemid 37462177)
27. Liebowitz MR, DeMartinis NA, Weihs K, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 2003;64:785-92 (Pubitemid 36897215)
28. FDA Approved Labeling for Zoloft-for the Treatment of Social Anxiety Disorder. Attachment to FDA Approval Letter for NDA 19-839/S-045. Washington, DC: FDA/Center for Drug Evaluation and Research, 2003. Available from: http://www. accessdata.fda.gov/drugsatfda-docs/label/2003/020990s011lbl.pdf [Last accessed 30 March 2013]
29. Murdoch D, McTavish D. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992;44:604-24
30. Deák K, Takács-Novák K, Tihanyi K, Noszál B. Physico-chemical profiling of antidepressive sertraline: solubility, ionisation, lipophilicity. Med Chem 2006;2:385-9 (Pubitemid 44083132)
31. Walash MI, Belal FF, El-Enany NM, Elmansi H. Development and validation of stability indicating method for determination of sertraline following ICH guidlines and its determination in pharmaceuticals and biological fluids. Chem Cent J 2011;5:61. Available from: http://journal. chemistrycentral.com/content/ 5/1/61 [Last accessed 30 March 2013]
32. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50:345-50 (Pubitemid 32816947)
33. Comer AM, Figgitt DP. Sertraline: a review of its therapeutic use in post-traumatic stress disorder. CNS Drugs 2000;14:391-407
34. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997;283:1305-22 (Pubitemid 28016506)
35. Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996;307:117-19 (Pubitemid 26226293)
36. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. CNS Agents Med Chem 2009;9:197-204
37. Byerley WF, McConnel EJ, McCabe RT, et al. Chronic administration of sertraline, a selective serotonin uptake inhibitor, decreased the density of beta-adrenergic receptors in rat frontoparietal cortex. Brain Res 1987;421:377-81 (Pubitemid 18021650)
38. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9(Suppl 1):19-26 (Pubitemid 24107713)
39. DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 2002;41:1247-66 (Pubitemid 36026765)
40. Mandrioli R, Mercolini L, Saracino MA, Raggi MA. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr Med Chem 2012;19:1846-63
41. Harada Y, Kohara N, Imaeda T. Pharmacological, pharmacokinetic, and clinical profile of sertraline hydrochloride (Zoloft). Folia Pharmacol Jpn 2006;128:417-24 (Pubitemid 351420651)
42. Chen X, Duan X, Dai X, Zhong D. Development and validation of a liquid chromatographic/tandem mass spectrometric method for the determination of sertraline in human plasma. Rapid Commun Mass Spectrom 2006;20:2483-9 (Pubitemid 44258454)
43. Alderman J, Wolkow R, Chung M, Johnston HF. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry 1998;37:386-94 (Pubitemid 28162892)
44. MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev 2001;7:1-24 (Pubitemid 32280681)
45. Freeman MP, Nolan PE, Davis MF, et al. Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol 2008;28:646-53
46. Baker GB, Fang J, Sinha S, Coutts RT. Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants. Neurosci Biobehav Rev 1998;22:325-33 (Pubitemid 28194389)
47. Rudorfer MV, Potter WZ. The role of metabolites of antidepre ssants in the treatment of depression. CNS Drugs 1997;7:273-312 (Pubitemid 27195910)
48. Sprouse J, Clarke T, Reynolds L, et al. Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology 1996;14:225-31 (Pubitemid 26120551)
49. Doogan DP, Caillard V. Sertraline: a new antidepressant. J Clin Psychiatry 1988;49(Suppl):46-51
50. Ronfeld RA, Shaw GL, Tremaine LM. Distribution and pharmacokinetics of the selective 5-HT uptake blocker sertraline in man, rat and dog. Psychopharmacology (Berl) 1988;96(Suppl 1):269
51. Kobayashi K, Ishizuka T, Shimada N, et al. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 1999;27:763-6 (Pubitemid 29297771)
52. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 2005;33:262-70 (Pubitemid 40216594)
53. Rudberg I, Hermann M, Refsum H, Molden E. Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol 2008;64:1181-8
54. Wang J-H, Liu Z-Q, Wang W, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001;70:42-7 (Pubitemid 32678801)
55. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Human cytochromes mediating sertraline biotransformation: seeking attribution. J Clin Psychopharmacol 1999;19:489-93
56. Jacobsen NW, Brooks BW, Halling-Sørensen B. Suggesting a testing strategy for possible endocrine effects of drug metabolites. Regul Toxicol Pharm 2012;62:441-8
57. Madras BK, Fahey MA, Miller GM, et al. Non-amine-based dopamine transporter (reuptake) inhibitors retain properties of amine-based progenitors. Eur J Pharmacol 2003;479:41-51 (Pubitemid 37377874)
58. Wilner KD, Everson G, Foulds GH, et al. Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of hepatic impairment. Eur Neuropsychopharmacol 1996;6(Suppl 3):40-1
59. Wilner KD, Baris BA, Foulds GH, et al. Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of renal impairment. Eur Neuropsychopharmacol 1996;6(Suppl 3):41
60. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5
61. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32(Suppl 1):1-21 (Pubitemid 27107715)
62. Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet 1995;29(Suppl 1):10-18
63. Sproule BA, Otton SV, Cheung SW, et al. CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol 1997;17:102-6 (Pubitemid 27148305)
64. Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997;62:145-56 (Pubitemid 27373462)
65. Spina E, D'Arrigo C, Migliardi G, et al. Plasma risperidone concentrations during combined treatment with sertraline. Ther Drug Monit 2004;26:386-90 (Pubitemid 38989658)
66. Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996;11(Suppl 5):31-61 (Pubitemid 27049280)
67. Rapeport WG, Muirhead DC, Williams SA, et al. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry 1996;57(Suppl 1):24-8 (Pubitemid 26143031)
68. Rapeport WG, Williams SA, Muirhead DC, et al. Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 1996;57(Suppl 1):20-3 (Pubitemid 26144854)
69. Ziegler MG, Wilner KD. Sertraline does not alter the beta-adrenergic blocking activity of atenolol in healthy male volunteers. J Clin Psychiatry 1996;57:12-15 (Pubitemid 26143029)
70. Pinninti NR, de Leon J. Interaction of sertraline with clozapine. J Clin Psychophamacol 1997;17:119-20
71. Chong SA, Tan CH, Lee HS. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. J Clin Psychopharmacol 1997;17:68-9 (Pubitemid 27047277)
72. Haduch A, Wójcikowski J, Daniel WA. The effect of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and newer antidepressant drugs on the activity and level of rat CYP3A. Eur Neuropsychopharmacol 2006;16:178-86 (Pubitemid 43358008)
73. Daniel WA, Haduch A, Syrek M, Boksa J. Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during long-term treatment. Eur Neuropsychopharmacol 2006;16:580-7 (Pubitemid 44716661)
74. Haduch A, Wójcikowski J, Daniel WA. Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study. Pharmacol Rep 2008;60:957-65
75. Apseloff G, Wilner KD, Gerber N, Tremaine LM. Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet 1997;32(Suppl 1):37-42 (Pubitemid 27107718)
76. Lundmark J, Reis M, Bengtsson F. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. Ther Drug Monit 2000;22:446-54 (Pubitemid 30622118)
77. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997;32:22-30 (Pubitemid 27107716)
78. Musenga A, Kenndler E, Mercolini L, et al. Determination of sertraline and Ndesmethylsertraline in human plasma by means of capillary electrophoresis with laser-induced fluorescence detection. Electrophoresis 2007;28:1823-31 (Pubitemid 46909737)
79. Mauri MC, Laini V, Cerveri G, et al. Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:597-601 (Pubitemid 34252957)
80. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011;44:195-235
81. Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001;158:275-81 (Pubitemid 32116525)
82. Walker JR, Van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 2000;20:636-44
83. Blomhoff S, Haug TT, Hellstrøm K, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001;179:23-30
84. Haug TT, Blomhoff S, Hellstrøm K, et al. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. Br J Psychiatry 2003;182:312-18 (Pubitemid 36408282)
85. Bandelow B. Sertraline in social anxiety disorder. Depress Anxiety 2006;23:6-10
86. Compton SN, Grant PJ, Chrisman AK, et al. Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry 2001;40:564-71 (Pubitemid 32374274)
87. Schuurmans J, Comijs H, Emmelkamp PMG, et al. Long-term effectiveness and prediction of treatment outcome in cognitive behavioral therapy and sertraline for late-life anxiety disorders. Int Psychogeriatr 2009;21:1148-59
88. Kutcher S. A combination of cognitive-behavioural therapy and sertraline reduced anxiety in children more than either treatment alone. Evid Based Med 2009;14:83
89. Emslie GJ. Combination of cognitive behavioral therapy and sertraline is more effective than monotherapy for pediatric anxiety disorders. J Pediatry 2009;154:775-6
90. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a aline and exposure therapy in social phobia. Br J Psychiatry 2004;184:271-2
91. Connor KM, Davidson JRT, Chung H. Multidimensional effects of sertraline in social anxiety disorder. Depress Anxiety 2006;23:6-10
92. Hirschfeld RMA. Sertraline in the treatment of anxiety disorders. Depress Anxiety 2000;11:139-57 (Pubitemid 30612764)
93. Sheehan DV, Kamijima K. An evidence-based review of the clinical use of sertraline in mood and anxiety disorders. Int Clin Psychopharmacol 2009;24:43-60
94. Mullins CD, Shaya FT, Meng F, et al. Comparison of first refill rates among users of sertraline, paroxetine, and citalopram. Clin Ther 2006;28:297-305
95. Mullins CD, Shaya FT, Meng F, et al. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 2005;25:660-7 (Pubitemid 40604881)
96. Ueda N, Yoshimura R, Umene-Nakano W, et al. Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers. World J Biol Psychiatry 2009;10:832-5
97. Stahl SM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 2000;48:894-901
98. Segraves RT, Kavoussi R, Hughes AR, et al. Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment. J Clin Psychopharmacol 2000;20:122-8 (Pubitemid 30202352)
99. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-66 (Pubitemid 34456365)
100. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 2001;62(Suppl 3):10-21 (Pubitemid 32164676)
101. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-83 (Pubitemid 47001035)
102. Bakker MK. Increased risk of septal heart defects in newborns as a result of sertraline and citalopram intake during pregnancy. Evid Based Mental Health 2010;13:58
103. Stowe ZN, Hostetter AL, Owens MJ, et al. The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. J Clin Psychiatry 2003;64:73-80 (Pubitemid 36182233)
104. Dodd S, Stocky A, Buist A, et al. Sertraline in paired blood plasma and breast-milk samples from nursing mothers. Hum Psychopharmacol 2000;15:261-4 (Pubitemid 30394357)
105. Vanderburg DG, Batzar E, Fogel I, Kremer CM. A pooled analysis of suicidality in double-blind, placebo-controlled studies of sertraline in adults. J Clin Psychiatry 2009;70:674-83
106. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008;30:1206-27
107. Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996;153:820-2 (Pubitemid 26171680)
108. Gardner MJ, Baris BA, Wilner KD, Preskorn SH. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Clin Pharmacokinet 1997;32(Suppl 1):43-9 (Pubitemid 27107719)
109. Barbenel DM, Yusufi B, O'Shea D, Bench CJ. Mania in a patient receiving testosterone replacement post-orchidectomy taking St John's wort and sertraline. J Psychopharmacol 2000;14:84-6 (Pubitemid 30156545)
110. Mason BJ, Blackburn KH. Possible serotonin syndrome associated with tramadol and sertraline coadministration. Ann Pharmacother 1997;31:175-7 (Pubitemid 27074104)
111. Hoge EA, Ivkovic A, Fricchione GL. Generalized anxiety disorder: diagnosis and treatment. Br Med J (Online) 2012;345:art.n. e7500
112. Bengtsson F, Lundmark J, Nordin C. TDM of selective serotonin reuptake inhibitors treating depression in the elderly reduces drug doses and costs. Ther Drug Monit 1997;19:579
113. Mandrioli R, Raggi MA. Advances in the enantioseparation of second-generation antidepressant drugs by electrodriven methods. Electrophoresis 2006;27:213-21 (Pubitemid 43180946)
114. Mandrioli R, Raggi MA. Electrodriven methods for the enantioseparation of second-generation antidepressant drugs: an update. Electrophoresis 2008;29:252-9
115. Mandrioli R, Saracino MA, Ferrari S, et al. HPLC analysis of the second-generation antidepressant sertraline and its main metabolite N-desmethylsertraline in human plasma. J Chromatogr B 2006;836:116-19
116. Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012;73:953-9
117. Rothschild AJ, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol 2012;22:858-66
118. ClinicalTrials.gov identifier NCT01234558, Single IV dose of GLYX-13 in patients with treatment-resistant depression. Bethesda, MD: U.S. National Institutes of Health, 2012. Available from: http://www. clinicaltrials.gov/show/ NCT01234558 [Last accessed 30 March 2013]